Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Kindstar Globalgene Technology, Inc. ( (HK:9960) ) is now available.
Kindstar Globalgene Technology, Inc. reported a decrease in revenue and a significant net loss for the first half of 2025, attributed to external market pressures, increased operating costs, and losses from recent acquisitions. The company’s gross profit margin also declined due to these factors, impacting its financial performance and highlighting the challenges faced in maintaining profitability amidst a competitive market environment.
The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.
More about Kindstar Globalgene Technology, Inc.
Kindstar Globalgene Technology, Inc. operates in the biotechnology industry, focusing on providing specialized diagnostic testing services. The company is known for its advanced laboratory services and has been expanding its market presence through acquisitions.
Average Trading Volume: 1,052,242
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.55B
See more data about 9960 stock on TipRanks’ Stock Analysis page.